Accelerating Market Access: Three Trends Shaping Pharma’s Future

Posted by Ed Schoonveld on Mon, Dec 16, 2019

Dean Hakanson co-wrote this blog post with Ed Schoonveld.

Is the demand for value-based care merely superficial? Are the industry’s decision-making and incentive systems built to encourage clinical innovation? How will pharma companies rethink their pipelines to improve poor commercialization efforts?


>
Read More

The 2019 STAT Summit: ‘You Don’t Burn the House Down to Get Rid of Rats’

Posted by Ed Schoonveld on Tue, Nov 26, 2019

Many senior leaders in the healthcare and pharmaceutical space gathered at the inaugural STAT Summit on Nov. 21st at the MIT campus in Cambridge, Mass. The invitation-only summit featured an interesting mix of exciting medical scientific advances, including bionic limbs, artificial intelligence, the impact of real-world evidence on drug development, and patient testimonials regarding some great medical and pharmaceutical innovations.


>
Read More

The Access Journey

Posted by Ed Schoonveld on Thu, Feb 21, 2019

How do we devise an optimal strategy to ensure patient access to our treatments in an age of value and affordability? How do we incorporate the impact of payers, medical communities, providers, prescribers and patients in a framework that helps us make trade-offs for development and commercialization decisions? It’s time to start the “access journey.”


>
Read More

The WHO Report and Access to Cancer Medicines

Posted by Ed Schoonveld on Tue, Feb 05, 2019

The World Health Organization’s recently published report, “Pricing of Cancer Medicines and its Impacts,” has elevated the issue to the agenda of the WHO’s executive board and is likely to ignite a lot of debate and some potential actions. While the report raises some very legitimate concerns related to access to anti-cancer drugs for patients, it also falls short of understanding the pharmaceutical industry environment. Rather than simply blaming the industry, it would be more productive to understand what’s standing in the way of collaboration to address patient needs and then jointly try to develop realistic programs to resolve it.


>
Read More

2017 Fair Pricing Forum: The Message for Pharma CEOs

Posted by Ed Schoonveld on Tue, Jul 18, 2017

This article was originally published in the June 2017 issue of In Vivo.

Drug pricing continues to be a social and political dilemma that forms a divide between the drug industry on one side and medical community, governments and patients on the other side. Frustrations over the high cost of prescription drugs have resulted in a groundswell of government and private initiatives to increase transparency, analyze value through various frameworks or directly control pricing.


>
Read More